Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BCHO Pharma Inc. 〉Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)

Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)

Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)

Request for Collaboration
Overview
CHO-A04 is a humanized monoclonal antibody targeting a novel carbohydrate antigen specifically and highly expressed on more than 10 cancer types, including triple negative breast cancer (TNBC) and pancreatic cancer. CHO-A04 kills cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The proof-of-concept (POC) study for CHO-A04 has been well done, which shows that CHO-A04 has a potent anti-tumor activity both in vitro and in vivo.
Patent Portfolio
Collaboration Options
The global market for cancer drugs has hit $100 billion in annual sales and continue to expand each year. Among them, more than one-third of the total sales are attributed to therapeutic antibodies to date. CHO-A04 targets not only common cancer types like breast, lung and colorectal cancers, but also those rare types with unmet medical needs, such as TNBC and pancreatic cancer. Thus, as a novel first-in-class therapeutic antibody, CHO-A04 shows great potential to become CHO's blockbuster and share the huge market of cancer therapy.
People who like this also like
  • Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
  • Digital Surgical Guide & Artificial Teeth ServiceDigital Surgical Guide & Artificial Teeth Service
  • iSONOiSONO
  • New Project ManagementNew Project Management
  • Quantitative analysis of SMN1 and SMN2 genes based on DHPLCQuantitative analysis of SMN1 and SMN2 genes based on DHPLC
  • Homogeneous antibody drugs (CHO-H01, H02, H03)Homogeneous antibody drugs (CHO-H01, H02, H03)
  • Multiple-Phasic Release Technology (MPRT)Multiple-Phasic Release Technology (MPRT)
  • FuraprevirFuraprevir
  • LT1001LT1001
  • SB04SB04